KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

BACKGROUND: Although immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients with non‐small cell lung carcinoma (NSCLC), the potential association between Kirsten rat sarcoma viral oncogene homolog (K...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chengming, Zheng, Sufei, Wang, Zhanyu, Wang, Sihui, Wang, Xinfeng, Yang, Lu, Xu, Haiyan, Cao, Zheng, Feng, Xiaoli, Xue, Qi, Wang, Yan, Sun, Nan, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456691/
https://www.ncbi.nlm.nih.gov/pubmed/35811500
http://dx.doi.org/10.1002/cac2.12327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456691/
https://www.ncbi.nlm.nih.gov/pubmed/35811500
http://dx.doi.org/10.1002/cac2.12327

Ejemplares similares